CKS9
CKS9 is an M cell-targeting polypeptide with the amino acid sequence CKSTHPLSC, forming a 9-mer peptide via cyclization through a disulfide bond between the two cysteine residues. CKS9 is obtained through phage display technology screening and has high affinity for M cells. CKS9 can promote chitosan nanoparticles to cross M cells and enter the follicle-associated epithelium (FAE) of intestinal Peyer's patches (PP). CKS9 can be used in studies related to swine dysentery and oral delivery.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C39H64N12O13S2
- Peso molecular:973.13
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
In Vitro
CKS9 can be successfully grafted onto stearic acid esterified starch to form SES@CKS9-1 and SES@CKS9-2[1].
CKS9-modified SES exhibits stronger binding affinity to integrin α5β1 than unmodified SES. CKS9 mediates key hydrogen-bond interactions at the interface of the βI/β-propeller domain of integrin, suggesting that integrin α5β1 is a potential M cell receptor for CKS9[1].
CKS9 is conjugated with WSC via EDC/NHS, with a molar ratio of 6.37 mol%[2].
As the C-terminal component of a computationally designed multi-epitope oral vaccine against *Helicobacter pylori*, CKS9 targets intestinal epithelial microfold cells to enhance the intestinal barrier uptake of the vaccine[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
Peso molecular 973.13
-
Fòrmula C39H64N12O13S2
-
Sequence
Cys-Lys-Ser-Thr-His-Pro-Leu-Ser-Cys (Disulfide bridge:Cys1-Cys9)
-
Sequence Shortening
CKSTHPLSC (Disulfide bridge:Cys1-Cys9)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)